Home › Sakit ni Graves
Pag-aaral pangklinika para sa Sakit ni Graves na nagre-recruit sa U.S.
14 pag-aaral para sa Sakit ni Graves ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX8 pag-aaral
- Miami, FL7 pag-aaral
- Dallas, TX7 pag-aaral
- Asheville, NC5 pag-aaral
- San Antonio, TX5 pag-aaral
- Hialeah, FL4 pag-aaral
- El Paso, TX4 pag-aaral
- San Francisco, CA4 pag-aaral
- Washington, DC3 pag-aaral
- Havelock, NC3 pag-aaral
- Raleigh, NC3 pag-aaral
- Farmington Hills, MI3 pag-aaral
- Kansas City, MO3 pag-aaral
- Memphis, TN3 pag-aaral
- Wilmington, NC3 pag-aaral
- Doral, FL3 pag-aaral
- Akron, OH3 pag-aaral
- Las Vegas, NV3 pag-aaral
- McKinney, TX3 pag-aaral
- Tucson, AZ3 pag-aaral
- Orlando, FL3 pag-aaral
- Torrance, CA3 pag-aaral
- Jacksonville, FL3 pag-aaral
Ayos sa estado
- Arizona6 pag-aaral
- California10 pag-aaral
- Florida9 pag-aaral
- Georgia5 pag-aaral
- Illinois3 pag-aaral
- Kansas4 pag-aaral
- Kentucky3 pag-aaral
- Maryland3 pag-aaral
- Massachusetts3 pag-aaral
- Michigan5 pag-aaral
- Missouri3 pag-aaral
- Nevada4 pag-aaral
- New York6 pag-aaral
- North Carolina11 pag-aaral
- Ohio4 pag-aaral
- Pennsylvania4 pag-aaral
- Tennessee4 pag-aaral
- Texas9 pag-aaral
- Virginia4 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
Nagre-recruitPhase 3
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07661056A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07722546A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07570316Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT07682896A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT07018323NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
Nagre-recruitPhase 1
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT07305818Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT07885605Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 20, 2026 · NCT07753603A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06727604Preoperative Corticosteroids in Autoimmune Thyroid Disease
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT05435547Study of BHV-1300 in Graves' Disease
Nagre-recruitPhase 1
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06980649Telehealth Music Therapy for Adults With Endocrine Disorder and Depression
Nagre-recruit
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT07413874Evaluating an AI Tool for Detecting Thyrotoxic States
Nagre-recruitObservasyonal na pag-aaral
Edad 22 pataas · Lahat ng kasarian · Na-update Hun 1, 2026 · NCT07017907The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 23, 2024 · NCT06275373Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.